MARKET

AXSM

AXSM

Axsome
NASDAQ

Real-time Quotes | Nasdaq Last Sale

82.59
-3.25
-3.78%
Opening 14:23 07/09 EDT
OPEN
85.98
PREV CLOSE
85.84
HIGH
87.25
LOW
81.56
VOLUME
301.78K
TURNOVER
--
52 WEEK HIGH
109.94
52 WEEK LOW
13.64
MARKET CAP
3.06B
P/E (TTM)
-32.3553
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AXSM stock price target is 162.50 with a high estimate of 210.00 and a low estimate of 115.00.

EPS

AXSM News

More
Here's Why Axsome Therapeutics Fell 20.4% in the First Half of 2020
Motley Fool · 22h ago
3 Perfect 10 Healthcare Stocks That Have Plenty of Growth on Tap
TipRanks · 2d ago
What Kind Of Investors Own Most Of Axsome Therapeutics, Inc. (NASDAQ:AXSM)?
Simply Wall St. · 5d ago
Top Small Cap Stocks for July 2020
Investopedia · 06/29 17:53
Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation
Zacks · 06/29 17:49
Top Small Cap Stocks for July 2020
Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a short period of time, companies with market caps of up to $10
Investopedia · 06/29 16:53
Why Axsome Therapeutics Stock Is Sinking Today
MotleyFool.com · 06/29 04:00
Should You Buy These 3 Stocks Tackling Alzheimer's Disease?
MotleyFool.com · 06/29 04:00

Industry

Biotechnology & Medical Research
-0.32%
Pharmaceuticals & Medical Research
-0.69%

Hot Stocks

Symbol
Price
%Change

About AXSM

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
More

Webull offers kinds of Axsome Therapeutics Inc stock information, including NASDAQ:AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.